Search
ASCO 2026: BeOne Medicines presented at this year's meeting long-term data on Brukinsa in CLL and combo data with the company's Bcl-2. Chairman & CEO John V. Oyler discusses that and new modalities
He highlights the importance of the long term Brukinsa data, which is the top selling BTK inhibitor today. Plus, we discuss degraders, antibody-drug conjugates, and bispecifics.
May 31
Jefferies London: BeOne Medicines announced a phase 3 success for its HER2 bispecific today in gastric cancer. John Oyler walks us through that and the whole pipeline
He hit on earnings, the HER2, degraders, and what BeOne is looking for in potential partners. Coverage brought to you by
Nov 17, 2025
.png){kind=logo}